Table 4.

Comparison of median absorbed doses of ⁹⁰Y-ibritumomab tiuxetan for selected organs in mGy/MBq in different studies

	Liver	Spleen	Kidney	Lung	Red marrow	Whole body (mSv/MBq)
Current study	3.2 (1.5–6.6)	2.9 (1.8–3.6)	1.46 (0.99–1.88)	1.47 (1.07–1.82)	0.52 (0.49–0.58)	0.87 (0.70–1.06)
Wiseman et al. [13]	4.60 (2.20–11.0)	7.30 (3.50–26.0)	0.20 (<0.01–0.65)	1.90 (1.30–4.30)	0.65 (0.26–1.10)	0.54 (0.46–0.78)
Fisher et al. [14]	3.1 (2.3–6.6)	4.3 (0.98–9.0)	2.4 (1.4–3.9)	0.60 (0.31–1.6)	2.4 (1.7–4.5)	0.55 (0.44–0.81)
Shen et al. [21]	3.66 (2.11–11.62)	6.14 (1.82–17.76)	3.31 (1.95–4.65)	1.10 (0.41–2.31)	0.79 (0.32–1.22)	0.48 (0.24–0.86)
90Y-Zevalin®	4.8 (2.9–8.1)	9.4 (1.8–20.0)	0.1 (0.0–0.3)	2.0 (1.2–3.4)	1.3 (0.6–1.8)	0.5 (0.4–.07)